<DOC>
	<DOCNO>NCT01708889</DOCNO>
	<brief_summary>The purpose study determine effect renal impairment pharmacokinetics ( PK ) BMS-914143 .</brief_summary>
	<brief_title>Pharmacokinetic Study BMS-914143 Participants With Normal Renal Function Mild , Moderate , Severe End-stage Renal Dysfunction</brief_title>
	<detailed_description>Primary purpose : Protocol design evaluate effect renal impairment pharmacokinetics BMS-914143</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Normal renal function mild , moderate , severe endstage renal dysfunction History uncontrolled unstable cardiovascular , respiratory , gastrointestinal , hepatic , endocrine , hematopoietic , psychiatric neurological condition within 6 month Lambda administration History chronic liver disease include cirrhosis , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , primary biliary cirrhosis , etc History central nervous system neuropsychiatric disease . Subjects severe depression and/or uncontrolled psychiatric condition enrol study History suicide attempt within 5 year precede BMS914143 administration Inability tolerate subcutaneous injection Donation &gt; 400 mL blood within 8 week plasma within 4 week plan dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>